Marksans Pharma Share Price

Marksans Pharma

CMP as on 26-Nov-20 15:46

₹ 58.70
0.75 1.29%

Open

₹ 58.30

Turnover (lac)

₹ 1,014

Prev. Close

₹ 57.95

Day's Vol (shares)

₹ 17,28,133

Day's Range (₹)

₹ 57.30
₹ 59.40

CMP as on26-Nov-20 15:41

₹ 58.95
1.05 1.81%

Open

₹ 57.90

Turnover (lac)

₹ 37

Prev. Close

₹ 57.90

Day's Vol (shares)

₹ 2,36,465

Day's Range

₹ 57.35
₹ 59.35

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 28-Oct-2020 - -
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2020 ,inter alia, to consider and approve Unaudited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and half year ended 30th September, 2020.
Board Meeting - 30-Sep-2020 - -
Please be informed that appointment of Dr. Meena Rani Surana (DIN: 08863769) as an additional independent director has come to end on 29th September, 2020. Further, please be informed that the Board of Directors of the Company has today i.e. 30th September, 2020, reappointed Dr. Meena Rani Surana (DIN: 08863769), subject to approval of the members at the next Annual General Meeting of the Company, as an Additional (Category - Independent) Director of the Company for a term of five (5) consecutive years with effect from 30th September, 2020 not liable to retire by rotation.
Board Meeting - 03-Sep-2020 - -
Appointment of Independent Women Director
Board Meeting - 24-Jul-2020 - -
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2020 ,inter alia, to consider and approve Unaudited Financial Results of the Company (both Standalone and Consolidated) for the Quarter ended 30th June, 2020. Please be informed that the Board of Directors at its meeting held on 4th August, 2020 has, subject to approval of the shareholders at the ensuing Annual General Meeting, re-appointed Mr. Mark Saldanha (DIN: 00020983) as Managing Director of the Company for a period of five (5) years with effect from 6th October, 2020. Further, the Board of Directors at its meeting held on 4th August, 2020 has, subject to approval of the shareholders at the ensuing Annual General Meeting, re-appointed Mrs. Sandra Saldanha (DIN: 00021023) as Whole-time Director of the Company for a period of three (3) years with effect from 25th September, 2020. (As per BSE Announcement Dated on 21/8/2020)
Board Meeting - 23-May-2020 - -
Marksans Pharma Ltd has informed BSE that the Meeting of the Board of Directors of the Company will be held on June 02, 2020, to consider and approve the Annual Audited Financial Results of the Company (both Standalone and Consolidated) for the Financial Year ended March 31, 2020. The Board of Directors will also consider recommendation of dividend, if any, for the Financial Year 2019-20. Further as per the Insider Trading Code of the Company, the Trading Window for dealing in Companys shares has been closed for the Companys insiders from April 01, 2020 and will remain closed till Forty-Eight hours after the announcement of the Financial Results on June 02, 2020. MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2020 ,inter alia, to consider and approve This is to inform you that the Meeting of the Board of Directors of the Company will be held on Tuesday, 2nd June, 2020 at Mumbai, to consider and approve the Annual Audited Financial Results of the Company (both Standalone and Consolidated) for the Financial Year ended 31st March, 2020. The Board of Directors will also consider recommendation of dividend, if any, for the Financial Year 2019-20. Please note that as per the Insider Trading Code of the Company, the Trading Window for dealing in Companys shares has been closed for the Companys insiders from 1st April, 2020 and will remain closed till Forty-Eight hours after the announcement of the Financial Results on 2nd June, 2020. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Audited Financial Results (both Standalone and Consolidated) for the quarter and year ended 31st March, 2020 approved by the Board of Directors at its meeting held today i.e. 2nd June, 2020 along with Auditors Reports thereon. The meeting commenced at 10:00 a.m. and concluded at 11:00 a.m. In this connection, we hereby confirm that the Statutory Auditors have given their reports on the Audited Annual Financial Results for the financial year ended 31st March, 2020 (both Standalone and Consolidated) with unmodified opinion. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Audited Financial Results (both Standalone and Consolidated) for the quarter and year ended 31st March, 2020 approved by the Board of Directors at its meeting held today i.e. 2nd June, 2020 along with Auditors Reports thereon. The meeting commenced at 10:00 a.m. and concluded at 11:00 a.m. In this connection, we hereby confirm that the Statutory Auditors have given their reports on the Audited Annual Financial Results for the financial year ended 31st March, 2020 (both Standalone and Consolidated) with unmodified opinion. This is to inform you that the Board of Directors of the Company has, at its meeting held today i.e. Tuesday, 2nd June, 2020 at Mumbai, recommended dividend of Rs. 0.10 (Rupees Zero and Paise Ten) i.e. 10% per equity share of Re. 1/- each face value for the financial year ended 31st March, 2020, subject to approval of the shareholders in the ensuing Annual General Meeting. (As Per BSE Announcement Dated on 02.06.2020)
Board Meeting - 29-Jan-2020 - -
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2020 ,inter alia, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the quarter ended 31st December, 2019. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results for the quarter and nine months ended December 31st, 2019 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held today i.e. February 11, 2020 along with Limited Review Reports thereon. The meeting commenced at 12:00 p.m. and concluded at 12:50 p.m. In this connection, we hereby certify that the Auditors have given their reports on the Unaudited Financial Results for the quarter and nine months ended 31st December, 2019 (both Standalone and Consolidated) with unmodified opinion. (As Per BSE Announcement Dated 11.02.2020)